Document Detail


No-carrier-added versus carrier-added123I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity.
MedLine Citation:
PMID:  16425032     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: No-carrier-added (nca) MIBG is primarily associated with specific uptake (i.e. uptake-1 mechanism). We evaluated the hypothesis that nca MIBG will be less influenced by changes in extra-neuronal uptake (i.e. uptake-2 mechanism) compared with carrier-added (ca) MIBG. METHODS: No-carrier-added MIBG was compared with ca MIBG of two different manufacturers (ca MIBG-1 and ca MIBG-2, with a specific activity of 200 Mq/mumol and 40 MBq/mumol MIBG respectively) in rats (n=6 per group): controls, blocking uptake-1 (desipramine) and blocking uptake-2 (phenoxybenzamine hydrochloride). Dedicated pinhole SPECT was performed 2 h after injection of the radiotracer. After SPECT, biodistribution was assessed [% injected dose per gram tissue (%ID)]. RESULTS: No-carrier-added MIBG had the highest absolute cardiac uptake. Although a clear trend was observed, nca MIBG was not statistically significantly different from ca MIBG-1 (0.31+/-0.05 %ID vs 0.25+/-0.01 %ID,p=0.05). Blocking uptake-1 resulted in a significant decrease in absolute cardiac uptake only for nca MIBG (0.22+/-0.03 %ID,p=0.004). Blocking uptake-2 resulted in a significant reduction in ca MIBG-1 cardiac uptake (0.14+/-0.02 %ID,p=0.0001), but not in the cardiac uptake of nca MIBG or MIBG-2. SPECT showed the highest relative cardiac uptake for nca MIBG. Poor contrast between myocardium and surrounding tissue hampered assessment of relative cardiac uptake on SPECT of both ca MIBG-1 and ca MIBG-2. CONCLUSION: No-carrier-added MIBG yields a higher myocardial uptake than ca MIBG and is associated with a higher specific as well as a lower non-neuronal uptake. We therefore conclude that for the scintigraphic assessment of the myocardial sympathetic nervous system, nca MIBG is to be preferred over ca MIBG.
Authors:
Hein J Verberne; Kora de Bruin; Jan B A Habraken; G Aernout Somsen; Jos L H Eersels; Frits Moet; Jan Booij; Berthe L F van Eck-Smit
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2006-01-20
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  33     ISSN:  1619-7070     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-04-18     Completed Date:  2006-09-19     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  483-90     Citation Subset:  IM    
Affiliation:
Department of Nuclear Medicine, University of Amsterdam, F2-238, Academic Medical Center, PO Box 22700, 1100 DE, Amsterdam, The Netherlands. h.j.verberne@amc.uva.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3-Iodobenzylguanidine / chemistry,  diagnostic use*,  pharmacokinetics*
Animals
Feasibility Studies
Heart / innervation*,  radionuclide imaging*
Isotope Labeling / methods
Male
Metabolic Clearance Rate
Myocardium / metabolism*
Organ Specificity
Radiopharmaceuticals / chemical synthesis,  diagnostic use,  pharmacokinetics
Rats
Rats, Wistar
Sympathetic Nervous System / metabolism*,  radionuclide imaging*
Tissue Distribution
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 77679-27-7/3-Iodobenzylguanidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evolutionary comparison of the reproductive genes, DAZL and BOULE, in primates with and without DAZ.
Next Document:  Intracellular sodium increase and susceptibility to ischaemia in hearts from type 2 diabetic db/db m...